Our De-ESCALaTE HPV study, published recently in the Lancet, showed the cisplatin was more effective than cetuximab when combined with radiotherapy in the treatment of HPV-associated throat (oropharyngeal) cancer. So cisplatin remains the standard of care for these patients.
For the full article, please see:
Comments